X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs NOVARTIS - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. NOVARTIS WOCKHARDT LTD./
NOVARTIS
 
P/E (TTM) x -18.7 285.0 - View Chart
P/BV x 2.0 31.6 6.3% View Chart
Dividend Yield % 0.0 1.4 0.1%  

Financials

 WOCKHARDT LTD.   NOVARTIS
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-18
NOVARTIS
Mar-18
WOCKHARDT LTD./
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,012758 133.5%   
Low Rs532579 91.8%   
Sales per share (Unadj.) Rs355.9228.4 155.8%  
Earnings per share (Unadj.) Rs-60.331.7 -189.9%  
Cash flow per share (Unadj.) Rs-46.832.8 -142.7%  
Dividends per share (Unadj.) Rs0.0110.00 0.1%  
Dividend yield (eoy) %01.5 0.1%  
Book value per share (Unadj.) Rs257.8297.1 86.8%  
Shares outstanding (eoy) m110.6324.69 448.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.9 74.1%   
Avg P/E ratio x-12.821.1 -60.8%  
P/CF ratio (eoy) x-16.520.4 -80.9%  
Price / Book Value ratio x3.02.2 133.1%  
Dividend payout %031.5 -0.1%   
Avg Mkt Cap Rs m85,37916,505 517.3%   
No. of employees `0006.30.7 936.2%   
Total wages/salary Rs m9,3711,445 648.3%   
Avg. sales/employee Rs Th6,295.08,441.3 74.6%   
Avg. wages/employee Rs Th1,498.32,163.6 69.3%   
Avg. net profit/employee Rs Th-1,066.31,173.1 -90.9%   
INCOME DATA
Net Sales Rs m39,3695,639 698.2%  
Other income Rs m1,2021,718 70.0%   
Total revenues Rs m40,5717,357 551.5%   
Gross profit Rs m18-63 -29.3%  
Depreciation Rs m1,49525 5,910.3%   
Interest Rs m2,55555 4,620.1%   
Profit before tax Rs m-2,8301,575 -179.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m257792 32.5%   
Profit after tax Rs m-6,669784 -851.0%  
Gross profit margin %0-1.1 -4.2%  
Effective tax rate %-9.150.3 -18.1%   
Net profit margin %-16.913.9 -121.9%  
BALANCE SHEET DATA
Current assets Rs m33,7969,522 354.9%   
Current liabilities Rs m26,9173,296 816.7%   
Net working cap to sales %17.5110.4 15.8%  
Current ratio x1.32.9 43.5%  
Inventory Days Days7937 216.7%  
Debtors Days Days8928 313.9%  
Net fixed assets Rs m39,66446 86,226.2%   
Share capital Rs m553123 448.3%   
"Free" reserves Rs m27,9687,213 387.7%   
Net worth Rs m28,5227,336 388.8%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62011,105 735.0%  
Interest coverage x-0.129.5 -0.4%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.5 95.0%   
Return on assets %-5.07.6 -66.7%  
Return on equity %-23.410.7 -218.9%  
Return on capital %-7.722.2 -34.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80761 16,183.3%   
Fx outflow Rs m1,7893,630 49.3%   
Net fx Rs m8,019-3,570 -224.6%   
CASH FLOW
From Operations Rs m6841,610 42.5%  
From Investments Rs m6,302687 917.4%  
From Financial Activity Rs m-7,695-2,677 287.5%  
Net Cashflow Rs m-664-380 174.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.3 2.0 115.0%  
FIIs % 7.7 1.6 481.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 21.5 71.6%  
Shareholders   67,757 41,647 162.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   DIVIS LABORATORIES  GLENMARK PHARMA  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare WOCKHARDT LTD. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

WOCKHARDT LTD. Announces Quarterly Results (2QFY19); Net Profit Down 158.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, WOCKHARDT LTD. has posted a net profit of Rs 228 m (down 158.2% YoY). Sales on the other hand came in at Rs 11 bn (up 10.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Nov 20, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. 5-YR ANALYSIS

COMPARE WOCKHARDT LTD. WITH

MARKET STATS